Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate

Dimethyl fumarate (DMF) is an electrophilic compound previously called BG-12 and marketed under the name Tecfidera (®). It was approved in 2013 by the US Food and Drug Administration and the European Medicines Agency for the treatment of relapsing multiple sclerosis. One mechanism of action of DMF i...

Descripción completa

Detalles Bibliográficos
Autores principales: Satoh, Takumi, Lipton, Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730864/
https://www.ncbi.nlm.nih.gov/pubmed/29263788
http://dx.doi.org/10.12688/f1000research.12111.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730864/
https://www.ncbi.nlm.nih.gov/pubmed/29263788
http://dx.doi.org/10.12688/f1000research.12111.1

Ejemplares similares